Loading data for ATTO — first visit, this takes a few seconds.

Attovia Therapeutics, Inc. (ATTO)

NasdaqGM: ATTO · リアルタイム株価 · USD

25.55

+1.35 (5.58%)

終値時点： Sep 04, 2026, 8:00 PM

25.56

+0.04%

時間外: 7:36 PM

アラート

Alert

株価、主要な数字、最新ニュースをひとまとめにしたページです。

データがありません

買気配	n/a
時価総額	1.17B
売上高（TTM）	1.8M
純利益（TTM）	-70.1M
	0.00
	-1.64
	n/a
	-10.74
PBR（TTM）	-0.92
PSR（TTM）	647.99
決算発表日	Nov 11, 2026

売気配	n/a
出来高	311,049
平均出来高（20日）	463,569
始値	24.44
前日終値	24.20
当日レンジ	24.44 - 27.66
52週レンジ	16.15 - 27.66
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

ATTOについて

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch ...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Aug 5, 2026

従業員数 44

上場取引所 NasdaqGM

ティッカー ATTO

ウェブサイト https://www.attovia.com

企業情報の全文

業績

2025年のAttovia Therapeuticsの売上高は1.35Mで、前年の0からundefined%の増加でした。利益は-60.63Mで、52.33%の増加でした。

財務諸表

決算サプライズ

Attovia TherapeuticsはSep 2, 2026に四半期決算を発表しました：

売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.
EPSは -4.88 で、予想を下回りました -0.27, うち -Infinity% の前年比減少.

次回決算発表

Attovia Therapeutics, Inc.の決算発表予定日は Nov 11, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

株価が動いた理由

ニュース

6日前 · MT Newswires

Attovia Therapeutics Could Serve as Key Player in Immunology, Inflammation, RBC Says

Attovia Therapeutics' (ATTO) ATTOBODY platform should position the company as a key player in immuno

6日前 · The Fly

Deere upgraded, Lumentum initiated: Wall Street's top analyst calls

6日前 · 24/7 Wall St.

Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More

Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that cou...

1週間前 · Trefis

Moderna Stock Carries A Market Value Its Revenue Does Not Support

Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.

1週間前 · Trefis

Moderna Stock Had A Readout Waiting In Plain Sight

Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move.

2ページ中1ページ

Attovia Therapeutics, Inc. (ATTO)